RICHLAND, Wash., April 8, 2016 /PRNewswire/ — IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the Board of Directors has scheduled the Company’s Fiscal 2016 Annual Meeting of Shareholders (the “Annual Meeting”) for Wednesday, June 8, 2016. Shareholders of record as of the close of business on Thursday, April 14, 2016 will be entitled to notice of and to vote at the Annual Meeting.
The Annual Meeting date represents a change of more than 30 days from the anniversary of the Company’s Fiscal 2015 Annual Meeting of Shareholders. As a result, the Company has set a deadline of April 18, 2016 for the receipt of any shareholder proposals for inclusion in the Company’s proxy materials. Proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended, must comply with the requirements set forth in Rule 14a-8. Shareholder proposals not submitted pursuant to Rule 14a-8 must comply with the requirements set forth in the Company’s bylaws. The Company intends to view any proposals received after April 18, 2016 as not having been received within the time periods set forth in Rule 14a-8 or the Company’s bylaws, as applicable. Any proposal submitted outside this timeframe will not be considered timely and will be excluded from consideration at the Annual Meeting.
Proposals and notices of proposals should be mailed to: IsoRay, Inc., 350 Hills Street, Suite 106 Richland, WA 99354, Attn: Corporate Secretary.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.